Franklin Resources Inc. Lowers Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Franklin Resources Inc. trimmed its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 1.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,323,803 shares of the company’s stock after selling 18,697 shares during the quarter. Franklin Resources Inc.’s holdings in Dyne Therapeutics were worth $31,189,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. abrdn plc purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth $608,000. Geode Capital Management LLC boosted its holdings in Dyne Therapeutics by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after buying an additional 84,760 shares during the period. Barclays PLC increased its stake in Dyne Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 207,309 shares of the company’s stock worth $7,446,000 after buying an additional 128,246 shares in the last quarter. State Street Corp raised its holdings in Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Dyne Therapeutics in the third quarter valued at about $1,067,000. Institutional investors own 96.68% of the company’s stock.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders sold 6,237 shares of company stock valued at $77,760. Company insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on DYN shares. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Chardan Capital reiterated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Piper Sandler dropped their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Finally, Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.46.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $8.28 on Friday. The stock has a market cap of $936.64 million, a price-to-earnings ratio of -2.33 and a beta of 1.21. The stock has a 50 day moving average price of $12.81 and a 200-day moving average price of $22.61. Dyne Therapeutics, Inc. has a one year low of $8.15 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. Sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.